Discontinued Product

Zotepine (Cat. No. 3996) has been withdrawn from sale for commercial reasons.
Cat.No. 3996 - Zotepine | C18H18ClNOS | CAS No. 26615-21-4
Description: 5-HT2A antagonist; also D2 and H1 antagonist; atypical antipsychotic
Chemical Name: 2-[(8-Chlorodibenzo(Z)[b,f]thiepin-10-yl)oxy]-N,N-dimethylethanamine
Purity: ≥99% (HPLC)
Literature (6)

Biological Activity for Zotepine

5-HT2A receptor and dopamine D2 receptor antagonist (Ki values are 0.69 and 2.3 nM respectively). Also a potent histamine H1 receptor antagonist (IC50 = 8.0 nM). Atypical antipsychotic; exhibits antidepressive and anxiolytic effects in vivo.

Technical Data for Zotepine

M. Wt 331.86
Formula C18H18ClNOS
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 26615-21-4
PubChem ID 5736
Smiles ClC3=CC=C2SC1=CC=CC=C1C=C(OCCN(C)C)C2=C3

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References for Zotepine

References are publications that support the biological activity of the product.

Herrick-Davis et al (2000) Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors. J.Pharmacol.Exp.Ther. 295 226 PMID: 10991983

Yamamura et al (2009) Effects of zotepine on extracellular levels of monamine, GABA and glutamate in rat prefrontal cortex. Br.J.Pharmacol. 157 656 PMID: 19371334

Shobo et al (2010) Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of NE reuptake. J.Pharmacol.Exp.Ther. 333 772 PMID: 20223878

View Related Products by Product Action

View all 5-HT2A Receptor Antagonists

Keywords: Zotepine, Zotepine supplier, 5-HT2A, serotonergic, dopamine, dopaminergic, D2, histamine, H1, receptors, antagonists, 5-HT2A/D2, atypical, antipsychotic, Receptors, Histamine, 3996, Tocris Bioscience

Citations for Zotepine

Citations are publications that use Tocris products.

Currently there are no citations for Zotepine.

Reviews for Zotepine

There are currently no reviews for this product. Be the first to review Zotepine and earn rewards!

Have you used Zotepine?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
5-HT Receptors

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.


Cardiovascular Poster

Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.


Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.


Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.